Mark G. Ward

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Extended High-Dose Tofacitinib Induction Improves Clinical Response in Ulcerative Colitis: A Multicenter Cohort Study.

Extended High-Dose Tofacitinib Induction Improves Clinical Response in Ulcerative Colitis: A Multicenter Cohort Study.

Journal: JGH open : an open access journal of gastroenterology and hepatology

Published: March 12, 2026

Gut Microbiota Are More Strongly Associated With Impairments in Health-Related Quality of Life Than Disease Activity in Inflammatory Bowel Disease.

Gut Microbiota Are More Strongly Associated With Impairments in Health-Related Quality of Life Than Disease Activity in Inflammatory Bowel Disease.

Journal: The American journal of gastroenterology

Published: May 19, 2025

Review Article: Albumin and Its Role in Inflammatory Bowel Disease: The Old, the New, and the Future.

Review Article: Albumin and Its Role in Inflammatory Bowel Disease: The Old, the New, and the Future.

Journal: Journal of gastroenterology and hepatology

Published: September 02, 2024

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial.

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial.

Journal: BMJ open

Published: July 20, 2024

Overcoming Immunogenicity to Anti-TNF Therapy by Reactively Adding an Immunomodulator.

Overcoming Immunogenicity to Anti-TNF Therapy by Reactively Adding an Immunomodulator.

Journal: Digestive diseases and sciences

Published: July 18, 2024

Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial.

Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: December 28, 2023

Mimics of inflammatory bowel disease: commonly encountered differentials of an uncommon condition.

Mimics of inflammatory bowel disease: commonly encountered differentials of an uncommon condition.

Journal: The Medical journal of Australia

Published: October 17, 2023

Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions.

Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions.

Journal: eGastroenterology

Published: July 03, 2023

Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.

Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.

Journal: Inflammatory bowel diseases

Published: June 08, 2023

Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics.

Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics.

Journal: Journal of clinical medicine

Published: September 30, 2022

Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?

Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: September 12, 2022

Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point of Care Using Rapidly Assessed Drug Levels in Patients with Inflammatory Bowel Disease.

Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point of Care Using Rapidly Assessed Drug Levels in Patients with Inflammatory Bowel Disease.

Journal: Therapeutic drug monitoring

Published: June 02, 2022

Showing 1-12 of 44

Last Updated: 09/26/2026